Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,289 across all filing types
Latest filing 2021-08-17 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物第三届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Zhengzhou Antu Bioengineering Co., Ltd. It details the convening and decisions of the third board's 24th meeting, including approval of the 2021 semi-annual report and other internal governance matters. The document is short (1077 characters) and references that detailed reports are disclosed on the Shanghai Stock Exchange website, indicating this is an announcement of board meeting resolutions rather than the full reports themselves. The content focuses on board decisions and meeting procedures, fitting the category of Board/Management Information (MANG).
2021-08-17 Chinese
安图生物2021年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 年半年度报告' which translates to '2021 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, company information, and operational details for the period January 1, 2021 to June 30, 2021. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data. The content matches the characteristics of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and provides comprehensive financial and operational information. There is no indication that this is merely an announcement or a certification document, so it should not be classified as RPA or RNS. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2021-08-17 Chinese
安图生物2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2021 半年度报告摘要' which translates to '2021 Half-Year Report Summary'. It contains financial data for the half-year period, including total assets, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report on the official website. The content includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. The document length is 2579 characters, which is relatively short but contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2021-08-17 Chinese
安图生物第三届监事会第二十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Zhengzhou Antu Bioengineering Co., Ltd. It reports on the approval of the 2021 semi-annual report and a special report on the use of raised funds. The document states that the detailed reports are disclosed on the Shanghai Stock Exchange website, indicating this document itself is an announcement of the meeting resolutions rather than the full semi-annual report or the special report. The document length is short (1024 characters), and it primarily announces the passing of resolutions and refers readers to the full reports elsewhere. Therefore, it fits best as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Report Publication Announcement (RPA), since it contains substantive content about the meeting and approvals but does not include the full reports themselves.
2021-08-17 Chinese
安图生物关于公司第三届董事会第二十四次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors regarding the company's use of raised funds in the first half of 2021. It references compliance with regulations on the use of raised funds and confirms no misuse or misleading information. The document is short (454 characters) and serves as an opinion or certification related to a specific report (the special report on raised funds usage). It does not contain substantive financial data or the full report itself. This fits best under Regulatory Filings (RNS) as it is a regulatory compliance statement and independent opinion rather than a full report or announcement of voting results.
2021-08-17 Chinese
安图生物子公司管理制度
Governance Information Classification · 95% confidence The document is titled '子公司管理制度' which translates to 'Subsidiary Management System' and contains detailed internal policies and procedures for managing subsidiaries of the company. It includes chapters on general principles, organizational structure, personnel management, financial and operational management, investment and guarantee management, information disclosure, internal audit supervision, and assessment and reward systems. There are no financial statements, earnings data, or regulatory filings. The document is a governance and management policy document rather than a financial report or announcement. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified under Governance Information (CGR) as it details the company's internal rules, board structure, and governance practices related to subsidiaries.
2021-08-17 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.